Pages that link to "Q40551071"
Jump to navigation
Jump to search
The following pages link to Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models (Q40551071):
Displaying 50 items.
- The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis (Q26797117) (← links)
- Epidermal growth factor receptor inhibitors: coming of age (Q27030769) (← links)
- EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS (Q27322781) (← links)
- Skin toxicities associated with epidermal growth factor receptor inhibitors (Q28245414) (← links)
- From bench to bedside: lessons learned in translating preclinical studies in cancer drug development (Q28533949) (← links)
- A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD (Q28548244) (← links)
- The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC). (Q33437650) (← links)
- Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells (Q34055939) (← links)
- Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo (Q34072567) (← links)
- Mechanisms of cutaneous toxicities to EGFR inhibitors. (Q34567916) (← links)
- Preclinical testing of erlotinib in a transgenic alveolar rhabdomyosarcoma mouse model. (Q34929504) (← links)
- Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma (Q35025478) (← links)
- Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice (Q35558962) (← links)
- Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians (Q35628121) (← links)
- Photodynamic therapy-induced angiogenic signaling: consequences and solutions to improve therapeutic response (Q35766780) (← links)
- Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma (Q35800541) (← links)
- Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms (Q35920966) (← links)
- Therapeutic targeting of receptor tyrosine kinases in lung cancer (Q36158717) (← links)
- Assays for membrane tyrosine kinase receptors: methods for high-throughput screening and utility for diagnostics (Q36192716) (← links)
- Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. (Q36220747) (← links)
- Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer (Q36302860) (← links)
- Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials (Q36385229) (← links)
- Targeting HER1/EGFR in cancer therapy: experience with erlotinib (Q36429516) (← links)
- New and emerging radiosensitizers and radioprotectors (Q36508097) (← links)
- Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors (Q36547786) (← links)
- A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. (Q36696463) (← links)
- Recent advances in targeted therapy for non-small cell lung cancer. (Q36709566) (← links)
- Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity (Q37015793) (← links)
- Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study (Q37119406) (← links)
- EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality (Q37174372) (← links)
- EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy (Q37609988) (← links)
- Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity (Q37657640) (← links)
- Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects (Q37730661) (← links)
- Reviewing the safety of erlotinib in non-small cell lung cancer (Q37817466) (← links)
- Erlotinib: as maintenance monotherapy in non-small-cell lung cancer (Q37868006) (← links)
- Erlotinib : a guide to its use in first-line treatment of non-small-cell lung cancer with epidermal growth factor-activating mutations (Q38075484) (← links)
- Erlotinib for the treatment of brain metastases in non-small cell lung cancer (Q38770028) (← links)
- Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292 (Q38776168) (← links)
- Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine. (Q39205736) (← links)
- Combination therapy using oral S-1 and targeted agents against human tumor xenografts in nude mice (Q39280635) (← links)
- Preclinical evaluation of the novel multi-targeted agent R1530. (Q39546167) (← links)
- Epidermal growth factor receptor signaling in nonsmall cell lung cancer (Q39752055) (← links)
- The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition (Q40154652) (← links)
- Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model (Q40181544) (← links)
- Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. (Q40340043) (← links)
- Inhibition of epidermal growth factor receptor tyrosine kinase ameliorates collagen-induced arthritis (Q42568723) (← links)
- Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models (Q43056152) (← links)
- Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects (Q46555261) (← links)
- Follicular rash during therapy with erlotinib (Tarceva). (Q48429767) (← links)
- Antagonism between Gefitinib and Cisplatin in Non-small Cell Lung Cancer Cells: Why Randomized Trials Failed? (Q48924990) (← links)